是否只有 BRCA 突变患者才能接受雄激素受体通路抑制剂和 PARP 抑制剂联合治疗转移性去势抵抗性前列腺癌？答案是否定的。
Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No.
发表日期：2024 Aug 17
作者：
Fred Saad
来源：
European Urology Focus
摘要：
从雄激素受体途径抑制剂和 PARP 抑制剂联合治疗中获益最多的患者是具有 BRCA 突变的患者，但当然也有一些没有 BRCA 突变的患者将从这种治疗策略中受益。版权所有 © 2024。由 Elsevier B.V. 出版。
Patients who benefit the most from combinations of an androgen receptor pathway inhibitor and a PARP inhibitor are those with a BRCA mutation, but there are certainly patients without BRCA mutations who will benefit from this treatment strategy.Copyright © 2024. Published by Elsevier B.V.